Nasdaq:US$36.56 (-0.93) | HKEX:HK$58.70 (+0.05) | AIM:£5.38 (-0.09)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors